CLDX R&D Expenses
Celldex Therapeutics Inc · R&D Expenses
CLDX R&D Expenses
Latest reported$67.55Mperiod ending
CLDX Quarterly R&D Expenses ($0.00 → $67.55M)
Quarterly R&D Expenses
High-resolution chart · PNG
CLDX r&d expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expenses (USD) |
|---|---|
| 67,549,000 | |
| 73,001,000 | |
| 75,359,000 | |
| 62,931,000 | |
| 54,196,000 | |
| 52,614,000 | |
| 46,120,000 | |
| 45,263,000 | |
| 38,890,000 | |
| 30,886,000 | |
| 30,426,000 | |
| 34,535,000 | |
| 26,252,000 | |
| 26,798,000 | |
| 22,899,000 | |
| 21,572,000 | |
| 20,731,000 | |
| 17,056,000 | |
| 14,678,000 | |
| 17,057,000 | |
| 12,356,000 | |
| 12,720,000 | |
| 28,425,000 | |
| 10,708,000 | |
| 13,205,000 | |
| 11,695,000 | |
| 10,339,000 | |
| 11,101,000 | |
| 10,081,000 | |
| 11,151,000 | |
| 11,207,000 | |
| 11,918,000 | |
| 21,448,000 | |
| 21,875,000 | |
| 23,464,000 | |
| 21,915,000 | |
| 24,999,000 | |
| 25,793,000 | |
| 24,558,000 | |
| 25,009,000 | |
| 25,711,000 | |
| 27,447,000 | |
| 23,900,000 | |
| 24,656,000 | |
| 26,490,000 | |
| 25,125,000 | |
| 27,026,000 | |
| 26,185,000 | |
| 24,100,000 | |
| 27,070,000 | |
| 17,804,000 | |
| 20,417,000 | |
| 15,090,000 | |
| 14,090,000 | |
| 13,748,000 | |
| 11,769,000 | |
| 11,114,000 | |
| 10,769,000 | |
| 9,824,000 | |
| 8,594,000 | |
| 7,169,000 | |
| 6,853,000 | |
| 6,742,000 | |
| 7,215,000 | |
| 7,256,000 | |
| 6,438,000 | |
| 2,440,000 | |
| 7,241,000 | |
| 7,802,000 | |
| 8,685,941 | |
| 7,603,836 | |
| 6,626,059 | |
| 7,611,666 | |
| 4,486,774 | |
| 4,111,982 | |
| 4,457,475 | |
| 4,967,629 | |
| 8,086 | |
| 4,837,466 | |
| 4,416,320 | |
| 4,463,899 | |
| 4,348,707 | |
| 3,010,351 | |
| 3,591,334 | |
| 3,430,992 | |
| 4,030,618 | |
| 4,247,000 | |
| 2,805,800 | |
| 3,367,800 | |
| 3,453,200 | |
| 2,145,300 | |
| 2,510,100 | |
| 2,673,400 | |
| 2,692,500 | |
| 2,809,300 | |
| 3,423,200 | |
| 4,066,400 | |
| 4,409,600 | |
| 6,445,100 | |
| 5,633,100 |